Peptide And Oligonucleotide CDMO Market Size, Share & Trends Analysis Report By Product (Peptides, Oligonucleotides), By Service Type, By End Use (Pharmaceutical Companies, Biopharmaceutical Companies), By Region, And Segment Forecasts, 2024 - 2030

Peptide And Oligonucleotide CDMO Market Size, Share & Trends Analysis Report By Product (Peptides, Oligonucleotides), By Service Type, By End Use (Pharmaceutical Companies, Biopharmaceutical Companies), By Region, And Segment Forecasts, 2024 - 2030

Peptide And Oligonucleotide CDMO Market Growth & Trends

The global peptide and oligonucleotide CDMO market is expected to reach USD 5.67 billion by 2030, according to a new report by Grand View Research, Inc. , registering a CAGR of 12.5% from 2024 to 2030. The growing recognition of peptides and oligonucleotides as valuable therapeutic agents for various diseases is fueling the demand for CDMO services. Moreover, the increasing pipeline of peptides and oligonucleotide therapeutics and the growing penetration of CDMOs in the field are a few of the factors driving the growth of the market.

The market is fragmented, with several players having similar technological and processing capabilities. These companies offer various services related to peptide and oligonucleotide development, data interpretation, sample analysis, and clinical trial support. The market is characterized by fierce competition driven by factors such as quality assurance, technological advancements, regulatory compliance, and the ability to offer high-value and diverse services.

The growing investment by major companies in the development and manufacturing of peptides and oligonucleotide-based therapeutics is one of the prominent factors supporting the growth of the market. For instance, in September 2023, CordenPharma announced the expansion of its commercial peptide production capabilities through the enhancement of facilities at CordenPharma Colorado, which now stands as the world's largest Solid-Phase Peptide Synthesis (SPPS) manufacturing facility. Additionally, in September 2023, CombiGene selected AmbioPharm as the CDMO partner for their peptide-based pain project, COZY01, which also involves Zyneyro.

The COVID-19 pandemic moderately impacted the market. The early stages of the COVID-19 pandemic had a notable impact on clinical trials, as a result of travel restrictions, disruptions in the supply chain, and setbacks in clinical trials. Nonetheless, it also presented prospects, notably the heightened emphasis on antiviral peptides and the swift creation of mRNA vaccines. Furthermore, there has been a substantial increase in collaborations and partnerships across biopharmaceutical companies with an aim to boost the production of peptide-based therapeutics.

Peptide And Oligonucleotide CDMO Market Report Highlights

• The peptides segment accounted for the largest share of 66.3% in 2023.The segment is driven by the growing demand for peptide-based therapeutics and the rise in the number of clinical trials involving the use of peptides.
• Based on the service type, the contract manufacturing segment accounted for the largest share of 65.0% in 2023. The substantial market share in this segment primarily results from the growing demand for outsourced manufacturing services, driven by the cost-effectiveness of outsourced manufacturing.
• Biopharmaceutical companies are anticipated to witness the highest CAGR of 13.0% across the analysis timeframe due to the increasing number of biopharmaceutical companies focusing on research and development of peptide-based drugs.
• Asia Pacific is anticipated to witness the highest CAGR of 13.4% during the forecast time frame. The substantial growth is primarily attributed to the rising trend of Western pharmaceutical companies outsourcing their manufacturing operations to emerging economies like China and India.

Please note The report will be delivered in 4-6 business days upon order notification.